Greenwich LifeSciences Q2 Loss Widens to $3.95M; Cash at $8.88M, Going Concern Warning Reiterated
GLSI sits 100% above its 52-week low of $7.78.
Summary
Greenwich LifeSciences posted a wider Q2 loss and reiterated its going concern warning, while cash rose to $8.88 million after selling $9.34 million in stock through its ATM program.
Key Events · Earnings and Guidance · GLSI
-
Q2 Loss Widens
Net loss of $3.95M ($0.27/share) vs $3.75M ($0.28/share) in Q2 2025, driven by higher R&D expenses.
-
Cash Raised via ATM
Sold 379,762 shares at average $25.36 for $9.34M net proceeds in H1 2026, boosting cash to $8.88M.
-
Going Concern Warning Reiterated
Management states substantial doubt about ability to continue as a going concern; future operations depend on raising additional capital.
-
Material Weaknesses Persist
Disclosure controls and procedures remain ineffective due to inadequate segregation of duties and insufficient accounting policies.
Analysis · GLSI · Life Sciences
A wider Q2 net loss of $3.95 million, up from $3.75 million a year ago, reflects rising R&D costs at Greenwich LifeSciences. The quarter ended with $8.88 million in cash, bolstered by $9.34 million raised through ATM stock sales at an average price of $25.36 per share. Management reiterated the going concern warning, emphasizing that continued operations hinge on securing additional capital. Material weaknesses in internal controls remain unresolved. In a subsequent move, the board extended the insider lock-up to January 31, 2027, barring pre-IPO shareholders from selling until that date.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GLSI was trading at $15.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $228.2M. The 52-week trading range was $7.78 to $34.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.